Printer Friendly

GRACE ANNOUNCES LICENSE OF TECHNOLOGY TO JOHNSON & JOHNSON

 BOCA RATON, Fla., Jan. 7 /PRNewswire/ -- W. R. Grace & Co. (NYSE: GRA) today announced that a subsidiary has agreed in principle to license a patented wound-treatment product to Johnson & Johnson Medical Ltd. in the U.K. on a worldwide, exclusive basis. Terms of the agreement were not disclosed.
 The product, which is intended for treatment of burns and chronic wounds, has undergone early-stage preclinical evaluations that prove its effectiveness. It offers a more cost-effective and less painful method of treating wounds than current surgical procedures.
 The product is a successful spin-off of research efforts at Grace in the mid-eighties to develop technologies in protein chemistry. Dr. Nils Friis, director of Business Development in Grace's Commercial Development Division, said, "Although there is a substantial and growing market for this product, we chose not to commercialize it directly as it does not fit with Grace's recently defined strategic objectives. We are pleased to have reached this agreement with Johnson & Johnson, a company uniquely positioned to market the product on a worldwide basis."
 Grace is the world's largest specialty chemicals company with a leadership position in health care.
 -0- 1/7/93
 /CONTACT: Chuck Suits of W.R. Grace & Co., 407-362-2600 or 800-GRACE99/
 (GRA JNJ)


CO: W.R. Grace & Co.; Johnson & Johnson Medical Ltd. ST: Florida IN: MTC SU: LIC

AW-JJ -- FL008 -- 2577 01/07/93 10:29 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 7, 1993
Words:226
Previous Article:HOME SHOPPING NETWORK POSTPONES ANNUAL MEETING; ANNOUNCES JUSTICE DEPARTMENT REQUEST
Next Article:MEDICAL PROPERTIES INC. ISSUES STATEMENT
Topics:


Related Articles
ALLIANCE PHARMACEUTICAL CORP. ANNOUNCES LICENSING AGREEMENT WITH ORTHO BIOTECH INC./R.W. JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE
ALLIANCE PHARMACEUTICAL CORP. ANNOUNCES LICENSING AGREEMENT WITH ORTHO BIOTECH INC./R.W. JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE
Johnson & Johnson Gains Marketing Rights to Novel Class of Compounds for Treating Pain and inflammation
Genetronics Announces Development and License Agreement with Ethicon, Inc.
Corvas to Receive $1 Million from Sale of Assets and License to Tissue Factor Patents to Johnson & Johnson Subsidiaries.
SK Corporation Announces CNS Licensing Agreement with Janssen Research Foundation.
Amgen wins dialysis arbitration against J&J, awarded $150 million.
J&J ordered to pay Amgen's costs and attorneys' fees.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters